SRX-3225

N/A

Report date: 2022/03/02 18:05:08
NME

Base Information

Drug NameSRX-3225
Drug Alias NameSRX-3225
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain-containing protein 4 inhibitorsPI3-kinase class I inhibitorsHistone deacetylase 6 inhibitors
TargetsPI3-kinase class IBromodomain-containing protein 4Histone deacetylase 6
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSignalrx Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSignalrx Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A